TECHNOLOGY SEED

  • Immune disease
  • Cancer
  • Life science

Are you looking for a novel target for cancers and autoimmune diseases? STAP-2 would be an answer.

eyecatch image

STAP-2 (signal-transducing adaptor protein-2) is a promising
therapeutic target because it is involved in various intracellular
signaling as an adaptor protein.

 

Our Findings on the STAP-2

  • 1. STAP-2 mediates proliferation of cancer cells through stabilization of the EGFR.

sample image

STAP-2 is highly expressed and stabilizes the EGFR in various cancer cells. We have successfully identified binding site for the STAP-2 and EGFR. In fact, the peptides for the binding site suppressed tumor growth in vitro and in vivo.
This binding site information can be beneficial not only for the peptide optimization for drug development, but also for small molecule inhibitors.

  • 2. STAP-2 enhances TCR (T cell Ag receptor) signaling.

sample image

STAP-2 promotes T cell activity by binding to CD3 and LCK, which are components of the TCR, thereby enhancing their functions. Our researchers have identified binding site for the STAP-2 to TCR components. And also, the binding inhibitory peptides for the site improved treatment of autoimmune diseases in vitro and in vivo.
Our findings on the STAP-2 will open up new possibilities for treatment of autoimmune diseases with peptides and small molecule inhibitors.

Feature

  1. We have identified a novel target for Cancer and autoimmune diseases.
  2. We have information on the binding sites for STAP-2 and TCR, EGFR.
  3. We have much data and know-how to support for developing clinical stage.

 

We are looking for a partner that will license in our IP and move our new findings forward to the clinical development. We can share more data with you under CDA and provide you with our peptides for your evaluation under MTA. Collaborative research is also available.

 

Data

The designed peptides demonstrated directly suppressing the EFGR and TCR signaling by the following experiments:

  • A binding site information for the STAP-2 and EGFR, TRC
  • Data for suppressive peptide sequences
  • STAP-2 peptides data for the T cell proliferation
  • Anti-EAE effect in vivo
  • Anti-tumor effect in vitro and in vivo

Applications:
Treatment of Cancer and autoimmune diseases

 

Patents

2022-504728（Japan）
17/761255（US）
21863087.9（Europe）
PCT/JP2022/004920（PCT）

BACK
CONTACT
Boston